

Effects of SCH 58261, an Adenosine A_{2A} Receptor Antagonist, on Quinpirole-Induced Turning in 6-Hydroxydopamine-Lesioned Rats: Lack of Tolerance after Chronic Caffeine Intake

Patrizia Popoli, M.D., Rosaria Reggio, and Antonella Pèzzola

In unilaterally 6-hydroxydopamine (6-OHDA)-lesioned rats, a rodent model of Parkinson's disease (PD), the adenosine A_{2A} receptor antagonist SCH 58261 significantly increased (+180%, $p < .01$) the number of rotations induced by a low dose of quinpirole (a dopamine D_2 receptor agonist), while it did not significantly modify the effects of a comparably low dose of SKF 38393 (a dopamine D_1 receptor agonist). The dose-dependent potentiating effects of SCH 58261 on quinpirole-induced turning were similar in caffeine-treated rats (1 g/l in drinking water over 14 days) and control animals (tap water). The selective potentiating

effects of SCH 58261 on D_2 -dependent turning confirm the existence of a potent and specific A_{2A}/D_2 receptor-receptor interaction. The persistence of the potentiating effects of SCH 58261 after chronic caffeine intake suggests that no tolerance should develop towards the antiparkinsonian effects of adenosine A_{2A} receptor antagonists with chronic treatment. [Neuropsychopharmacology 22:522–529, 2000] © 2000 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

KEY WORDS: Adenosine A_{2A} receptors; Dopamine D_1 and D_2 receptors; Parkinson's disease; Chronic caffeine treatment.

The two major output pathways from the basal ganglia, the direct (striato-nigral) and the indirect (striato-pallidal) pathways, have opposing effects on thalamocortical neurones and subsequently on motor activity (Alexander and Crutcher 1990). A co-ordinated balance of the pathway functions results in normal movements,

while predominance of the indirect or the direct pathways is thought to underlie hypo- and hyper-kinetic disorders, respectively (Albin et al. 1989). For instance, over-activity of the indirect pathway (due to the reduction of dopamine D_2 receptor-mediated inhibition of striato-pallidal neurones) is thought to determine the motor deficits of Parkinson's disease (PD) (Alexander and Crutcher 1990; Gerfen et al. 1990).

In the striato-pallidal neurones, dopamine D_2 receptors are co-localized with adenosine A_{2A} receptors (Fink et al. 1992; Schiffmann et al. 1991; Svenningsson et al. 1997a), and a tonic, antagonistic A_{2A}/D_2 interaction has been reported. The stimulation of A_{2A} receptors decreases the affinity of D_2 receptors for the agonist in rat striatal membranes (Ferré et al. 1991b) and in a mouse fibroblast cell line stably cotransfected with A_{2A} and D_2 receptors (Dasgupta et al. 1996). Adenosine A_{2A} receptor agonists inhibit, while A_{2A} receptor antagonists po-

From the Pharmacology Department (PP, RR, AP), Istituto Superiore di Sanità Viale Regina Elena 299, 00161 Rome Italy.

Address correspondence to: Dr. Patrizia Popoli, Pharmacology Department, Istituto Superiore di Sanità Viale Regina Elena 299, 00161 Rome Italy. Tel.: +39-06-49902482; Fax: +39-06-49387104; E-mail: patrizia.popoli@iss.it

Received July 29, 1999; revised October 11, 1999; accepted November 11, 1999.

tentiate, the effects of D₂ receptor agonists on motor activity, neurotransmitter release and striatal c-Fos expression (Ferré et al. 1991a, 1993, 1999; Jin et al. 1993; Morelli et al. 1995; Pollack and Fink 1995). While much data indicates that A_{2A} receptors selectively interact with dopamine D₂ receptors (reviewed in Ferré et al. 1997), adenosine A_{2A} receptor blockade has been reported to potentiate both D₁- and D₂-dependent contralateral rotations in 6-hydroxydopamine (6-OHDA)-lesioned rats (Fenu et al. 1997; Pinna et al. 1996). One of the possible explanations for these findings is a synergistic D₁-D₂ interaction occurring due to a direct stimulation of D₁ receptors (by the D₁ receptor agonist) and a facilitation of D₂ receptors (by the removal of a tonic A_{2A}-dependent inhibition). If A_{2A} receptor blockade directly potentiated D₂-mediated responses while only indirectly potentiated D₁-mediated effects, we would expect the effects elicited by very low doses of D₁ and D₂ receptor agonists to be modulated differently by A_{2A} receptor blockade.

Due to the key role played by adenosine A_{2A} receptors in the regulation of striatal dopaminergic neurotransmission, drugs acting on these receptors are likely to be useful in the treatment of neurological disorders related to dopaminergic dysfunction (Ferré et al. 1992; Ongini and Fredholm 1996). In particular, adenosine A_{2A} receptor blockade is likely to counteract (through the potentiation of D₂ receptor-mediated effects) the over-activity of the indirect pathway in PD. In fact, adenosine A_{2A} receptor antagonists have recently been proposed as potential new agents for treating this disease (Richardson et al. 1998). The current PD treatment is based almost entirely on dopamine replacement therapy using L-dopa but the occurrence of dyskinesia and/or psychosis and the loss of efficacy over time greatly impair the therapeutic benefit of this drug. Although adenosine A_{2A} receptor antagonists may be a very promising therapeutic alternative, tolerance may develop due to chronic administration. In fact chronic treatment with caffeine, a non-selective adenosine receptor antagonist, has been shown to induce tolerance to the motor stimulating effects of caffeine in rodents (Garrett and Holtzman 1995a,b; Nikodijevic et al. 1993a,b), and to caffeine-induced c-Fos expression in the rat globus pallidus (Svenningsson and Fredholm 1997).

The first aim of this paper was to evaluate whether SCH 58261, a selective adenosine A_{2A} receptor antagonist (Zocchi et al. 1996), influenced differently the turning behavior elicited by comparably low doses of D₁ (SKF 38393) and D₂ (quinpirole) receptor agonists in rats unilaterally lesioned with 6-OHDA, a rodent model of PD (Schwartz and Huston 1996; Ungerstedt 1971). Secondly, we aimed to evaluate whether the potentiating effects of SCH 58261 were reduced by chronic adenosine receptor blockade.

METHODS

Experimental Protocol

Male Sprague-Dawley rats (145–155 g) were used. The animals were kept under standardized temperature, humidity and lighting conditions, with free access to water and food. Animal care and use followed the directives of the Council of the European Communities (86/609/EEC). Under Equithesin (3 ml/kg) anaesthesia, animals were placed in a Kopf stereotaxic apparatus. Unilateral injections of 6-hydroxydopamine (8 µg / 4 µl of 0.2% ascorbic acid saline solution) were performed in the left nigrostriatal pathway (coordinates with respect to bregma: A = −2.4; L = +1.2; V = −7.8 mm) by means of a Hamilton syringe (mod. 701). Starting 3 weeks after the lesion, the animals' ability to rotate in response to apomorphine (0.05 mg/kg subcutaneously) was tested. Contralateral rotations induced by apomorphine were measured 3–4 times at weekly intervals. Only animals showing at least 50 turns/ 5 min in the last test were included in the study. Thirty minutes prior to starting the experiments, the animals were placed in rotation bowls in a soundproof experimental room. Each trial was analysed by an observer unaware of the treatment received by the animals. Only complete (360°) and uninterrupted turns were recorded over 60 min.

Dose-response effects of Dopamine D₁ and D₂ Receptor Agonists

The ability of different doses of SKF 38393 and quinpirole to induce contralateral rotations was evaluated in groups of 6–8 lesioned rats each. Low doses of both drugs (1/5 of the minimal dose inducing a maximal effect) were selected for the subsequent experiments aimed at evaluating the potentiating effects of SCH 58261.

Influence of SCH 58261 on Quinpirole- and SKF 38393-Induced Turning

Either quinpirole (0.02 mg/kg) or SKF 38393 (0.6 mg/kg) were administered intraperitoneally (i.p.) 15 min after SCH 58261 (2 mg/kg i.p.) or vehicle (*n* = 8 in both groups). The dose of SCH 58261 used in these experiments was selected on the basis of a previous study (Popoli et al. 1998).

Chronic Caffeine Treatment

To test whether chronic caffeine intake affected the ability of SCH 58261 to potentiate quinpirole-induced rotations, the effects of three different doses of SCH 58261 were tested in both caffeine-treated and control rats. A

caffeine solution (1 g/l in drinking water) was administered over 14 consecutive days to lesioned rats. The dose of caffeine was chosen on the basis of previous reports (Garrett and Holtzman 1995a, b; Holtzman et al. 1991). Animals had free access to drinking bottles over the entire period. The daily caffeine intake was determined twice a week by weighing each bottle on consecutive days at 9.30 A.M.; a difference of 1 g in weight was assumed to represent 1 ml of caffeine solution consumed. Control rats received normal drinking water. At the end of chronic treatment, both caffeine-treated and control rats received SCH 58261 (0, 0.5, 1 and 2 mg/kg i.p.) plus quinpirole (0.02 mg/kg). Each group was made up of eight animals.

Drugs

Anhydrous caffeine base (Sigma) was dissolved in tap water. (\pm)-SKF 38393 hydrochloride ((\pm)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride, RBI) and (-)-Quinpirole hydrochloride (RBI) were dissolved in distilled water. SCH 58261 [7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidine] (Schering Plough, Milan, Italy) was dissolved in dimethyl-sulfoxide (DMSO). CPT (8-Cyclopentyltheophylline, RBI), was dissolved in water with a minimal amount of 0.1N NaOH.

Statistics

One-way ANOVA followed by Dunnett's test, and Student's *t* test were used to assess the statistical significance between groups.

RESULTS

Dose-Response Curves of Dopamine D₁ and D₂ Receptor Agonists

Both quinpirole and SKF 38393 (Figure 1) induced dose-dependent contralateral rotations in 6-OHDA-lesioned rats. The minimal doses inducing a maximal effect were 0.1 mg/kg of quinpirole and 3 mg/kg of SKF 38393.

Influence of SCH 58261 on the Turning Behavior Elicited by Low Doses of D₁ and D₂ Receptor Agonists

The adenosine A_{2A} receptor antagonist SCH 58261 (2 mg/kg) potentiated significantly the contralateral rotations induced by a low dose (0.02 mg/kg) of quinpirole (Figure 2). On the contrary, the effects of a low dose (0.6 mg/kg) of SKF 38393 were not significantly potentiated by SCH 58261 (Figure 2). In order to verify whether the lack of potentiating effects of SCH 58261 towards SKF

38393-induced rotations could merely be ascribed to the high inter-individual variability (as suggested by the large S.E.M) of the effects elicited by this dose of SKF 38393, two additional sets of experiments were performed. First, the ability of N⁶-cyclopentyl-theophylline (CPT, a selective adenosine A₁ receptor antagonist) to potentiate the turning behavior induced by SKF 38393 0.6 mg/kg was tested in 6 rats. CPT (7.2 mg/kg, 15 min before) increased significantly the number of contralateral rotations induced by SKF 38393 (Figure 3, left). In a second series of experiments, the influence of SCH 58261 on the turning behavior induced by a higher dose (1.2 mg/kg) of SKF 38393 was studied. SCH 58261 was unable to potentiate significantly the turning induced by SKF 38393 1.2 mg/kg (Figure 2). Neither SCH 58261 2 mg/kg nor CPT 7.2 mg/kg induced turning when administered alone (*n*=5 in each group, data not shown).

Chronic Caffeine Treatment

In rats treated chronically with caffeine, an average daily intake of 65 mg/kg was estimated. The average body weight of caffeine-treated rats was comparable to the average weight of rats in the control group. In both caffeine-treated and control rats, SCH 58261 potentiated quinpirole-induced turning in a dose-dependent way, the dose-response effects of SCH 58261 being very similar in the two groups (Figure 4). At a dose of 2 mg/kg, SCH 58261 increased significantly quinpirole-induced rotations (+180% and 175% in caffeine-treated and control rats, respectively), while a non significant potentiation was observed with a dose of 1 mg/kg.

The number of contralateral rotations induced by quinpirole 0.02 mg/kg was not reduced by chronic caffeine intake. Since chronic caffeine treatment had been previously reported to induce tolerance to the effects of quinpirole in 6-OHDA-lesioned rats (Garrett and Holtzman 1995b), additional experiments were performed to verify whether tolerance to the effects of a fully-effective dose of quinpirole developed. Two groups of 8 rats each were treated with quinpirole 0.1 mg/kg after having received caffeine or drinking water for 14 days. The number of quinpirole-induced contralateral rotations was reduced (-40%; *p* < .05 according to Student's *t* test) in caffeine-treated rats with respect to controls (data not shown).

Finally, in order to verify whether our "chronic" protocol was actually suitable to induce tolerance to the motor effects of selective adenosine receptor antagonists, the influence of CPT on SKF 38393-induced turning was also tested in a separate group of 6 caffeine-treated rats. Chronic caffeine intake abolished the potentiating effects of the selective adenosine A₁ receptor antagonist (Figure 3, right).





Figure 1. Dose-response effects of quinpirole and SKF 38393 in 6-hydroxydopamine-lesioned rats. Each group was composed of 6–8 lesioned rats. Quinpirole or SKF 38393 were administered intraperitoneally (i.p.). Doses are expressed as mg/kg.



DISCUSSION

Influence of SCH 58261 on D₁- and D₂- Dependent Turning Behavior

In the present experiments, SCH 58261 potentiated significantly the effects of a low dose of quinpirole whereas it did not modify significantly the effects of a comparably low dose of SKF 38393. Although 0.02 mg/kg of quinpirole and 0.6 mg/kg of SKF 38393 induced approximately the same average number of rotations, the effects of SKF 38393 showed a greater inter-individual variability. This might indicate that the motor effects elicited by 0.6 mg/kg of SKF 38393 are poorly susceptible to potentiation irrespective of the treatment. However, the turning behavior induced by SKF 0.6

mg/kg could be markedly and significantly potentiated by the selective adenosine A₁ receptor antagonist CPT. Moreover, even the effects induced by a higher dose (1.2 mg/kg) of SKF 38393 were not potentiated by SCH 58261. This latter finding agrees with a previous report which shows the ineffectiveness of SCH 58261 (3 mg/kg) in potentiating the turning behavior induced by SKF 38393 1.5 mg/kg (Pinna et al. 1996). The finding that, at least in a particular range of doses, D₁-dependent turning behavior is not potentiated by adenosine A_{2A} receptor blockade does not support the view that a direct interaction between A_{2A} and D₁ receptors exists. Indeed, there is no direct evidence of a co-localization of these two receptors (Svenningsson et al. 1997a). Assuming that A_{2A} and D₁ receptors do not interact di-




Figure 2. Influence of SCH 58261 on the turning behaviour induced by quinpirole (0.02 mg/kg) and SKF 38393 (0.6 and 1.2 mg/kg) in 6-hydroxydopamine-lesioned rats. Either quinpirole or SKF 38393 were administered 15 min after SCH 58261 (2 mg/kg) or vehicle. Each group was composed of 6–8 animals. * $p = .01$ versus quinpirole (Student's t test).

rectly, the previously reported potentiating effects of A_{2A} receptor antagonists on D_1 -mediated rotations (Pinna et al. 1996) could depend on the disinhibition of D_2 -dependent response, leading to a D_1 - D_2 synergistic activation. Some evidence, however, suggests that this is not the only possible mechanism of the reported A_{2A} / D_1 interaction. First, in 6-OHDA-lesioned rats the pattern of striatal c-Fos expression following coadministration of a D_1 agonist and an adenosine antagonist was different from the c-Fos expression pattern observed following co-administration of D_1 and D_2 agonists (Pollack and Fink 1996). Moreover, the "synergistic" hypothesis can not explain the inhibitory effects exerted by certain doses of an A_{2A} receptor agonist on both D_1 - and D_2 -induced turning (Morelli et al. 1994). Since adenosine A_{2A} receptors modulate acetylcholine (Brown et al. 1990), GABA (Ferré et al. 1993) and glutamate release (Popoli et al. 1995), other indirect mechanisms may also account for the A_{2A} / D_1 interaction.

As for the ability of SCH58261 to selectively potentiate D_2 -dependent rotations, this finding is in line with a previous study showing that CGS 21680, an adenosine A_{2A} receptor agonist, antagonized quinpirole- but not SKF 38393-induced turning in 6-OHDA-lesioned rats (Ferré et al. 1999). Taken together, these results provide a behavioral support for the view that a specific antagonistic interaction exists between adenosine A_2 and dopamine D_2 receptors in the neostriatum (Ferré et al. 1991b), an interaction which was found to be even increased in 6-OHDA-lesioned rats (Ferré and Fuxe 1992).

In agreement with previous studies (Pinna et al. 1996), neither SCH 58261 nor CPT induced rotational behavior in themselves in 6-OHDA-lesioned rats. This finding, which is apparently at odds with the ability of non-selective adenosine receptor antagonists, such as caffeine, to induce turning behavior in the same model, may indicate that in the denervated striatum the residual dopaminergic tone at D_1 and D_2 receptors is too low





Figure 3. Influence of N⁶-cyclopentylthioephyllyline (CPT, 7.2 mg/kg) on the turning behaviour induced by SKF 38393 (0.6 mg/kg) in control and caffeine-treated 6-hydroxydopamine-lesioned rats. Left: ("control"): CPT (7.2 mg/kg, 15 min before) significantly potentiated SKF 38393-induced turning in control rats. Right: "chronic caffeine": rats received caffeine (1 g/l in their drinking water) over 14 days. At the end of chronic treatment, they were treated with SKF 38393 alone (0.6 mg/kg) or CPT (7.2 mg/kg) plus SKF 38393. Each group was composed of six animals. * $p < .005$ versus SKF 38393 alone according to Student's t test.

A) Drinking water



B) Caffeine




Figure 4. Dose-response effects of SCH 58261 on quinpirole-induced turning in control and caffeine-treated rats. A) Control rats (which had received normal drinking water over 14 days) were treated with vehicle or SCH 58261 0.5, 1 and 2 mg/kg plus (15 min thereafter) quinpirole 0.02 mg/kg. B) Caffeine-treated rats received caffeine (1 g/l in their drinking water) over 14 days. At the end of chronic treatment, they received vehicle or SCH 58261 0.5, 1 and 2 mg/kg plus (15 min thereafter) quinpirole 0.02 mg/kg. Each group was composed of eight animals. * = $p < .05$ versus quinpirole (One-way ANOVA followed by Dunnett's test).

to become enhanced by selective A_1 and A_{2A} receptor blockade, respectively.

Influence of Chronic Caffeine Intake on the Effects of SCH 58261

One of the aims of the present study was to verify whether the ability of SCH 58261 to potentiate quinpirole-induced rotations in a rodent model of PD was reduced by chronic caffeine treatment. The best way to investigate whether tolerance could develop towards the effects of a selective A_{2A} receptor antagonist would

have been to use SCH 58261, instead of the non-selective antagonist caffeine, in chronic treatment. Unfortunately, SCH 58261 is not water-soluble, and performing daily injections of a DMSO solution would have been unethical due to the related irritating properties. On the other hand, since the effects of caffeine seem to mainly depend on the blockade of adenosine A_{2A} receptors (Svenningsson et al. 1997b), caffeine may be considered an acceptable alternative to an A_{2A} antagonist.

Although it was only possible to estimate the daily intake of caffeine, the mean caffeine intake noted here is similar to that reported by other authors who had used

a scheduled access protocol (Holtzman et al. 1991; Garrett and Holtzman 1994, 1995b). The development of tolerance to the effects elicited by quinpirole 0.1 mg/kg after chronic caffeine is also in accordance with a previous report (Garrett and Holtzman 1995b). Moreover, the finding that chronic caffeine intake abolishes the potentiating effects of CPT indicates that the experimental protocol used here was suitable for the purposes of the study.

The similarity of the dose-response curves of SCH 58261 plus quinpirole in caffeine-treated and control animals indicate that chronic adenosine receptor blockade does not induce tolerance to the potentiating effects of SCH 58261. Conversely, tolerance developed to the potentiating effects of an adenosine A_1 receptor antagonist. This differential influence of chronic caffeine intake on the effects of A_1 (tolerance) and A_{2A} (no tolerance) receptor antagonists is in line with several reports showing that A_1 , but not A_{2A} receptors, are up-regulated after chronic caffeine (reviewed in Jacobson et al. 1996). Moreover, although the motor effects of caffeine appear to depend mainly on the blockade of adenosine A_{2A} receptors (Svenningsson et al. 1997b), such receptors seem to be not involved primarily in the development of tolerance to the motor stimulating effects of caffeine after chronic administration (Garrett and Holtzman 1995a,b; Holtzman et al. 1991; Nikodijevic et al. 1993a,b).

The present finding of persistent potentiating effects of SCH 58261 after chronic adenosine receptor blockade is in full agreement with a recent report showing that the ability of KW-6002 (a selective A_{2A} receptor antagonist) to reverse motor defects in parkinsonian monkeys was maintained after chronic administration over 21 days (Kanda et al. 1998).

In conclusion, these results confirm that a potent and selective A_{2A}/D_2 interaction exists, and support the hypothesis that A_{2A} receptor blockade could be a suitable alternative approach to the treatment of PD.

ACKNOWLEDGMENTS

The authors thank Prof. Kjell Fuxe and Dr. Sergi Ferré (Department of Neuroscience, Karolinska Institute, Stockholm, Sweden) for helpful discussions throughout the study and Dr. Ennio Ongini (Schering Plough, Milan) for generously providing SCH 58261.

This work was supported by a coordinated European BIOMED 2 project (BM4-CT96-0238).

REFERENCES

Albin RL, Young AB, Penney JB (1989): The functional anatomy of basal ganglia disorders. *Trends Neurosci* 12:366–375

- Alexander GR, Crutcher MD (1990): Functional architecture and basal ganglia circuits: neural substrates of parallel processing. *Trends Neurosci* 13:266–271
- Brown SJ, James S, Reddington M, Richardson PJ (1990): Both A_1 and A_{2A} purine receptors regulate striatal acetylcholine release. *J Neurochem* 55:31–37
- Dasgupta S, Ferré S, Kull B, Hedlund PB, Finnman UB, Ahlberg S, Arenas E, Fredholm BB, Fuxe K (1996): Adenosine A_{2A} receptor modulate the binding characteristics of dopamine D_2 receptors in stably cotransfected fibroblast cells. *Eur J Pharmacol* 316: 325–331
- Fenu S, Pinna A, Ongini E, Morelli M (1997): Adenosine A_{2A} receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxy-dopamine-lesioned rats. *Eur J Pharmacol* 321:143–147
- Ferré S, Herrera-Marschitz M, Grabowska-Andén M, Casa M, Ungerstedt U, Andén NE (1991a): Postsynaptic dopamine/adenosine interaction. I. Adenosine analogues inhibit dopamine D_2 -mediated behaviour in short-term reserpinized mice. *Eur J Pharmacol* 192: 25–29
- Ferré S, Von Euler G, Johansson B, Fredholm B, Fuxe K (1991b): Stimulation of high affinity adenosine A_2 receptors decreases the affinity of dopamine D_2 receptors in rat striatal membranes. *Proc Natl Acad Sci USA* 88:7238–7241
- Ferré S, Fuxe K (1992): Dopamine denervation leads to an increase in the intramembrane interactions between adenosine A_2 and dopamine D_2 receptors in the neostriatum. *Brain Res* 594:124–130
- Ferré S, Fuxe K, Von Euler G, Johansson B, Fredholm BB (1992): Adenosine-dopamine interactions in the brain. *Neuroscience* 51:501–512
- Ferré S, O'Connor WT, Fuxe K, Ungerstedt U (1993): The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. *J Neurosci* 13:5402–5406
- Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997): Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. *Trends Neurosci* 20:482–487
- Ferré S, Popoli P, Rimondini R, Reggio R, Kehr J, Fuxe K (1999): Adenosine A_{2A} and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D_2 receptors in the rat striatum. *Neuropharmacol* 38:129–140
- Fink JS, Weaver DR, Rivkees SA, Peterfreund RA, Pollack A, Adler DM, Reppert SM (1992): Molecular cloning of the rat A_2 adenosine receptors: selective co-expression with D_2 dopamine receptors in rat striatum. *Mol Brain Res* 14:186–195
- Garrett BE, Holtzman SG (1994): Caffeine cross-tolerance to the selective dopamine D_1 and D_2 receptor agonists but not to their synergistic interaction. *Eur J Pharmacol* 262:65–75
- Garrett BE, Holtzman SG (1995a): Does adenosine receptor blockade mediate caffeine-induced rotational behaviour? *J Pharmacol Exp Ther* 274:207–214
- Garrett BE, Holtzman SG (1995b): The effects of dopamine agonists on rotational behavior in non-tolerant and caffeine-tolerant rats. *Behav Pharmacol* 6:843–851

- Gerfen CR, Engber TM, Mahan L, Susel Z, Chase TN, Monsma FJ, Sibley DR (1990): D1 and D2 dopamine receptor-regulated gene expression of strionigral and striopallidal neurons. *Science* 250:1429–1432
- Holtzman SG, Mante S, Minneman KP (1991): Role of adenosine receptors in caffeine tolerance. *J Pharmacol Exp Ther* 256:62–68
- Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, Kuwana Y, Jenner P (1998): Adenosine A_{2A} antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. *Ann Neurol* 43:507–513
- Jacobson KA, Von Lubitz DKJE, Daly JW, Fredholm BB (1996): Adenosine receptor ligands: differences with acute versus chronic treatment. *Trends Pharmacol Sci* 17:108–113
- Jin S, Johansson B, Fredholm BB (1993): Effects of adenosine A_1 and A_2 receptor activation on electrically evoked dopamine and acetylcholine release from rat striatal slices. *J Pharmacol Exp Ther* 267:801–808
- Morelli M, Fenu S, Pinna A, Di Chiara G. (1994): Adenosine A_2 receptors interact negatively with dopamine D_1 and D_2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. *Eur J Pharmacol* 251: 21–25
- Morelli M, Pinna A, Wardas J, Di Chiara G. (1995): Adenosine A_2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. *Neuroscience* 67: 49–55
- Nikodijevic O, Jacobson KA, Daly JW (1993a): Locomotor activity in mice during chronic treatment with caffeine and withdrawal. *Pharmacol Biochem Behav* 44:199–216
- Nikodijevic O, Jacobson KA, Daly JW (1993b): Effects of combinations of methylxanthines and adenosine analogs on locomotor activity in control and chronic caffeine-treated mice. *Drug Dev Res* 30:104–110
- Ongini E, Fredholm BB (1996): Pharmacology of adenosine A_{2A} receptors. *Trends Pharmacol Sci* 17:364–372
- Pinna A, Di Chiara G, Wardas J, Morelli M (1996): Blockade of A_{2A} receptors positively modulates turning behaviour and c-Fos expression induced by D_1 agonists in dopamine-denervated rats. *Eur J Neurosci* 8:1176–1181
- Pollack AE, Fink JS (1995): Adenosine antagonists potentiate D2-dopamine-dependent activation of Fos in the striopallidal pathway. *Neuroscience* 68:721–728
- Pollack AE, Fink JS (1996): Synergistic interaction between an adenosine antagonist and a D_1 dopamine agonist on rotational behavior and striatal c-Fos induction in 6-hydroxydopamine-lesioned rats. *Brain Res* 743:124–130
- Popoli P, Betto P, Reggio R, Ricciarello G (1995): Adenosine A_{2A} receptor stimulation enhances striatal extracellular glutamate levels in rats. *Eur J Pharmacol* 287: 215–217
- Popoli P, Reggio R, Pèzzola A, Fuxe K, Ferré S (1998): Adenosine A_1 and A_2 receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats. *Neurosci Lett* 251:201–204
- Richardson PJ, Kase H, Jenner PG (1998): Adenosine A_{2A} receptor antagonists as new agents for the treatment of Parkinson's disease. *Trends Pharmacol Sci* 18:338–344
- Schiffmann SN, Jacobs O, Vanderhaeghen JJ (1991): Striatal restricted adenosine A_2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an *in situ* hybridization histochemistry study. *J Neurochem* 57:1062–1067
- Schwartz PKW, Huston JP (1996): The unilateral 6-hydroxydopamine lesion model in behavioural brain research. Analysis of functional deficits, recovery and treatments. *Progr Neurobiol* 50:275–331
- Svenningsson P, Fredholm BB (1997): Caffeine mimics the effect of a dopamine $D_2/3$ receptor agonist on the expression of immediate early genes in globus pallidus. *Neuropharmacol* 36:1309–1317
- Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm BB (1997a): Cellular expression of adenosine A_{2A} receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. *Neuroscience* 80:1171–1185
- Svenningsson P, Nomikos G, Ongini E, Fredholm BB (1997b): Antagonism of adenosine A_{2A} receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. *Neuroscience* 79:753–764
- Ungerstedt U (1971): Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system in the rat brain. *Acta Physiol Scand* 82(Suppl. 367):69–93
- Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, Dionisotti S (1996): The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A_{2A} adenosine receptor antagonist. *J Pharmacol Exp Ther* 276:398–404